Puncturing The ImClone Hype

Puncturing The ImClone Hype
Could ImClone Systems’ Erbitux be a powerful cancer fighter after all? Maybe.

A new study presented June 1 at a meeting of oncologists seems to boost that contention. But there are still reasons to doubt that Erbitux will be approved soon or that it will eventually be a blockbuster.

Click here for reuse options!
Copyright 2003 Biotechblog

Leave a Reply

%d bloggers like this: